TITLE

The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells

AUTHOR(S)
Liu, Yinxing; Gilbert, Misty; Kyprianou, Natasha; Rangnekar, Vivek; Horbinski, Craig
PUB. DATE
November 2014
SOURCE
Acta Neuropathologica;Nov2014, Vol. 128 Issue 5, p723
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Prostate apoptosis response-4 (Par-4) is an endogenous tumor suppressor that selectively induces apoptosis in a variety of cancers. Although it has been the subject of intensive research in other cancers, less is known about its significance in gliomas, including whether it is regulated by key driver mutations, has therapeutic potential against glioma stem cells (GSCs), and/or is a prognostic marker. We found that patient-derived gliomas with mutant isocitrate dehydrogenase 1 have markedly lower Par-4 expression ( P < 0.0001), which was validated by The Cancer Genome Atlas dataset ( P = 2.0 E-13). The metabolic product of mutant IDH1, D-2-hydroxyglutarate (2-HG), can suppress Par-4 transcription in vitro via inhibition of promoter activity as well as enhanced mRNA degradation, but interestingly not by direct DNA promoter hypermethylation. The Selective for Apoptosis induction in Cancer cells (SAC) domain within Par-4 is highly active against glioma cells, including orthotopic xenografts of patient-derived primary GSCs ( P < 0.0001). Among high-grade gliomas that are IDH1 wild type, those that express more Par-4 have significantly longer median survival (18.4 vs. 8.0 months, P = 0.002), a finding confirmed in two external GBM cohorts. Together, these data suggest that Par-4 is a significant component of the mutant IDH1 phenotype, that the activity of 2-HG is complex and can extend beyond direct DNA hypermethylation, and that Par-4 is a promising therapeutic strategy against GSCs. Furthermore, not every effect of mutant IDH1 necessarily contributes to the overall favorable prognosis seen in such tumors; inhibition of Par-4 may be one such effect.
ACCESSION #
98950184

 

Related Articles

  • Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Chapuis, N.; Tamburini, J.; Green, A. S.; Willems, L.; Bardet, V.; Park, S.; Lacombe, C.; Mayeux, P.; Bouscary, D. // Leukemia (08876924);Oct2010, Vol. 24 Issue 10, p1686 

    Mammalian target of rapamycin (mTOR) is a protein kinase implicated in the regulation of various cellular processes, including those required for tumor development, such as the initiation of mRNA translation, cell-cycle progression and cellular proliferation. In a wide range of hematological...

  • Increased expression of cellular repressor of E1A-stimulated gene (CREG) in gastric cancer patients: a mechanism of proliferation and metastasis in cancer. Xu, Ling; Wang, Feng; Liu, Hua; Xu, Xuan-Fu; Mo, Wen-Hui; Xia, Yu-Jing; Wan, Rong; Wang, Xing-Peng; Guo, Chuan-Yong // Digestive Diseases & Sciences;Jun2011, Vol. 56 Issue 6, p1645 

    Background: The cellular repressor of E1A-stimulated genes (CREG), a secreted glycoprotein, has been studied with human embryonic carcinoma cells, vascular smooth muscle cells, and NIH3T3 fibroblasts. However, its relationship to tumor cell proliferation and metastasis has not been...

  • Integrated Analysis of Transcriptome in Cancer Patient-Derived Xenografts. Li, Hong; Zhu, Yinjie; Tang, Xiaoyan; Li, Junyi; Li, Yuanyuan; Zhong, Zhaomin; Ding, Guohui; Li, Yixue // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Patient-derived xenograft (PDX) tumor model is a powerful technology in evaluating anti-cancer drugs and facilitating personalized medicines. Multiple research centers and commercial companies have put huge efforts into building PDX mouse models. However, PDX models have not been widely...

  • HES6 gene is selectively overexpressed in glioma and represents an important transcriptional regulator of glioma proliferation. Haapa-Paananen, S; Kiviluoto, S; Waltari, M; Puputti, M; Mpindi, J P; Kohonen, P; Tynninen, O; Haapasalo, H; Joensuu, H; Perälä, M; Kallioniemi, O // Oncogene;3/8/2012, Vol. 31 Issue 10, p1299 

    Malignant glioma is the most common brain tumor with 16 000 new cases diagnosed annually in the United States. We performed a systematic large-scale transcriptomics data mining study of 9783 tissue samples from the GeneSapiens database to systematically identify genes that are most...

  • The Sulfatase Pathway for Estrogen Formation: Targets for the Treatment and Diagnosis of Hormone-Associated Tumors. Secky, Lena; Svoboda, Martin; Klameth, Lukas; Bajna, Erika; Hamilton, Gerhard; Zeillinger, Robert; Jäger, Walter; Thalhammer, Theresia // Journal of Drug Delivery;2013, p1 

    The extragonadal synthesis of biological active steroid hormones from their inactive precursors in target tissues is named "intracrinology." Of particular importance for the progression of estrogen-dependent cancers is the in situ formation of the biological most active estrogen,...

  • A Rare Breast Tumor: Dermatofibrosarcoma Protuberans. Özcan, Tevhide Bilgen; Hacıhasanoğlu, Ezgi; Nazlı, Mehmet Ali; Aksoy, Şefika; Leblebici, Cem; Talu, Canan Kelten // Meme Sagligi Dergisi / Journal of Breast Health;Jan2016, Vol. 12 Issue 1, p44 

    Dermatofibrosarcoma protuberans is a slow-growing, local aggressive fibrous tumor of the subcutaneous tissue, frequently seen in the proximal extremities and the trunk. Its occurrence in the breast is very rare. Herein, we present a female who presented with a breast mass, and aim to discuss...

  • Upregulation of Cleavage and Polyadenylation Specific Factor 4 in Lung Adenocarcinoma and Its Critical Role for Cancer Cell Survival and Proliferation. Chen, Wangbing; Guo, Wei; Li, Mei; Shi, Dingbo; Tian, Yun; Li, Zhenlin; Wang, Jingshu; Fu, Lingyi; Xiao, Xiangsheng; Liu, Quentin Qiang; Wang, Shusen; Huang, Wenlin; Deng, Wuguo // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Cleavage and polyadenylation specific factor 4 (CPSF4), a member of CPSF complex, plays a key role in mRNA polyadenylation and mRNA 3′ ends maturation. However, its possible role in lung cancer pathogenesis is unknown. In this study, we investigated the biological role and clinical...

  • Rola transportera glukozy 1 (GLUT1) w diagnostyce i terapii nowotworów. Jóźwiak, Paweł; Lipińska, Anna // Advances in Hygiene & Experimental Medicine / Postepy Higieny i ;2012, Vol. 66, p165 

    Malignant cells are known to enhance glucose metabolism, to increase glucose uptake and to inhibit the process of oxidative phosphorylation. Accelerated glycolysis is one of the biochemical characteristics of cancer cells that allow them to compensate the inefficient extraction of energy from...

  • Odontogenic keratocysts/keratocystic odontogenic tumours: biological characteristics, clinical manifestation and treatment. Pazdera, Jindrich; Kolar, Zdenek; Zboril, Vitezslav; Tvrdy, Peter; Pink, Richard // Biomedical Papers of the Medical Faculty of Palacky University i;Jun2014, Vol. 158 Issue 2, p170 

    Background. Odontogenic keratocysts (OKCs) now reclassified as Keratocystic odontogenic tumours (KCOTs) are a clinical entity with a characteristic microscopic picture, kinetic growth and biological behaviour. They arise from the proliferation of the epithelial dental lamina in both maxilla and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics